EOFlow’s subsidiary, Nephria Bio, has signed a license agreement with Drexel University on the transfer of new MXene nanomaterial technology. As a result, Nephria secured exclusive rights to use MXenes for the development of a wearable dialysis system, known as the wearable artificial kidney. As stated in the article by Drexel University, the technology could allow many of the millions of people suffering from end-stage kidney disease worldwide to move more freely, without spending hours each week anchored to large dialysis machines.
“Our fundamental study of titanium carbide MXene supported by NSF showed that MXene is biocompatible, able of adsorbing a variety of small molecules, and holds a lot of promise in medical applications, so it is exciting to see it applied for improving and really changing dialysis — an area of need in health care that can help millions of people,” said Yury Gogotsi, PhD, Distinguished University and Bach professor in Drexel’s College of Engineering, who is a world leader in developing and studying MXenes.
Click here to visit the full article by Drexel University →